Korro reports second quarter 2024 financial results and provides business updates

Cambridge, mass., aug. 13, 2024 (globe newswire) -- korro bio, inc. (korro) (nasdaq: krro), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing rna for both rare and highly prevalent diseases, today reported financial results for the second quarter of 2024 and provided an update on its recent progress and anticipated milestones.
KRRO Ratings Summary
KRRO Quant Ranking